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Estimation of adult antiretroviral treatment coverage in 
South Africa
Muhammad Aarif Adam, Leigh F Johnson
Death notification statistics confirm that AIDS is dramatically 
affecting mortality in South Africa.1 Demographic and 
epidemiological models suggest that antiretroviral treatment is 
the only intervention that can achieve a substantial reduction 
in AIDS mortality in South Africa in the short term.2,3 South 
Africa therefore urgently needs to expand and strengthen 
services providing antiretroviral treatment. Before 2004, access 
to antiretroviral drugs was limited mainly to medical scheme 
beneficiaries. However, following the announcement of a 
comprehensive care, management and treatment programme 
by the Department of Health (DoH) in late 2003,4 antiretroviral 
treatment has become increasingly accessible, and significant 
progress has been made in enrolling patients onto the public 
antiretroviral treatment programme. 
Despite this progress, there remains a significant unmet 
need for antiretroviral treatment in South Africa; monitoring of 
antiretroviral coverage is therefore important to identify where 
the shortfall is greatest and to quantify coverage according 
to different definitions of ‘need’. However, monitoring of 
antiretroviral coverage in South Africa is challenging for 
several reasons. Although the DoH regularly co-ordinates data 
collection for the public health sector, there is no centrally co-
ordinated data collection system for the private sector and non-
governmental organisations (NGOs). In addition, the numbers 
routinely reported by the DoH are the numbers of patients 
cumulatively enrolled on antiretroviral treatment, and there 
are no estimates of public-sector patients currently receiving 
antiretroviral treatment, except in the Western Cape. Coverage 
is also difficult to estimate because demographic projection 
models usually estimate only the numbers of individuals 
in different WHO clinical stages,2,5 whereas definitions of 
eligibility are usually based on a combination of clinical 
and CD4+ criteria.4,6,7 This makes it difficult to estimate the 
denominator in the antiretroviral coverage calculation.
Much is unknown regarding antiretroviral coverage in South 
Africa. The aim of this paper is to quantify the coverage in 
South Africa up to the middle of 2008, according to various 
definitions of antiretroviral treatment eligibility, and to 
quantify the relative levels of coverage in the nine provinces 
and the changing contribution of different providers to the 
antiretroviral rollout in South Africa.
Method
Following the convention of UNAIDS and the World Health 
Organization (WHO), antiretroviral coverage is calculated as 
the number of individuals receiving antiretroviral treatment, 
divided by the sum of the number of untreated individuals 
needing treatment and the number of treated individuals.8,9 
Estimates of the numbers receiving treatment are obtained 
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Objectives. To estimate the annual numbers of individuals 
receiving antiretroviral treatment in South Africa up to mid-
2008, and the coverage of antiretroviral treatment in adults 
according to various definitions of need.
Methods. Antiretroviral coverage is defined as the number 
of patients receiving antiretroviral treatment at a point in 
time, divided by the number needing treatment. Numbers of 
patients receiving antiretroviral treatment are estimated from 
public sector data, and data provided by disease management 
programmes and NGO programmes. The unmet need for 
treatment in adults is estimated using a Markov model of HIV 
progression in adults, combined with estimates of annual new 
HIV infections from a national AIDS and demographic model.
Results. By the middle of 2008, 568 000 adults and children 
were receiving antiretroviral treatment in South Africa, with 
the public health sector accounting for 79% of this total. 
Using the current Department of Health criteria for defining 
antiretroviral eligibility (CD4+ count <200/µl or World Health 
Organization (WHO) stage 4), antiretroviral coverage in 
adults was 40.2% in 2008 – up from 4.9% in 2004. Coverage 
increases to 54.2% if eligibility is based on WHO stage 4 only, 
but falls to 22.2% if the Southern African HIV Clinicians 
Society guidelines are used to define eligibility. Coverage in 
2008 varied between provinces, from 25.8% in the Free State 
to 71.7% in the Western Cape.
Conclusions. Significant progress has been made in expanding 
access to antiretroviral treatment in South Africa since 2004, 
but a substantial unmet need for treatment in adults remains.
S Afr Med J 2009; 99: 661-667.
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from public sector programme reports and data collected 
from the private sector, while estimates of the unmet need for 
treatment are derived from a model of HIV progression in HIV-
infected individuals. Although numbers receiving treatment are 
calculated for both adults and children, antiretroviral coverage 
is calculated for adults only, since definitions of antiretroviral 
eligibility and rates of HIV progression differ between children 
and adults.
Estimation of numbers receiving antiretroviral 
treatment
Estimates of the numbers of patients starting antiretroviral 
treatment each year in public health facilities are obtained from 
unpublished reports of the cumulative numbers of patients 
who have started antiretroviral treatment at different times 
(Department of Health internal report dated 7 May 2009: 
National Strategic Plan for HIV and AIDS/CCMT monthly 
statistics, March 2009).10 To allow for mortality and loss to 
follow-up after starting treatment, rates of retention are applied 
to these annual numbers of individuals starting therapy. 
Based on estimates of retention in the Western Cape,11 it is 
assumed that the probability of remaining on treatment for the 
first 6 months after starting therapy is 0.895, and the annual 
probability of remaining on treatment thereafter is 0.935. The 
number of individuals receiving treatment at time t (in years) is 
thus calculated as:
N(t) = N(t–1) × 0.935 + S(t–1) × 0.895  (1)
where S(t–1) is the number of individuals starting treatment 
between time t – 1 and time t. It is assumed that individuals 
starting treatment between time t – 1 and time t do so, on 
average, at time t – ½.
Estimates of the numbers of patients receiving antiretroviral 
treatment through disease management programmes (DMPs), 
workplace treatment programmes (WPTPs) and NGO 
programmes operating outside of public health facilities are 
based on three data sources:
1.    early published data from Aid for AIDS,12 which was 
treating approximately 80% of all antiretroviral patients in 
200213
2.    early data on NGO programmes operating before 200414
3.    more recent data collected from individual programmes 
from 2005 to 2008.15
Since programmes do not provide estimates at regular 
intervals, and since information is missing for some 
programmes during certain periods, estimates of numbers of 
patients receiving treatment at the middle of each year are 
obtained by using linear interpolation and extrapolation of 
estimates at other time points. The number of individuals 
starting treatment between time t – 1 and time t, S(t–1), is 
estimated by entering the private sector estimates of N(t–1) and 
N(t) into equation (1) and assuming that the rates of retention 
in the private sector16,17 are the same as those in the Western 
Cape.
For some years, data on the provincial distribution of 
treatment numbers are not available. In these years, we 
assumed that the proportion of individuals treated in a 
particular province, and for a given sector (private/public/
NGO), was the same as that estimated in the most recent year. 
For the public and NGO sectors, the most recent provincial 
distributions are for 2008. For the private sector, a provincial 
distribution could be obtained only for 2003, based on a 
weighting of the 2003 population5 by the proportion of 
the population with medical cover18 and the proportion of 
medically insured individuals on antiretroviral treatment.12
Estimation of unmet need for treatment
The unmet need for treatment was estimated by using a 
Markov model of HIV progression that divides HIV-infected 
adults into compartments based on their current CD4+ count, 
clinical status and current receipt of antiretroviral treatment 
(Fig. 1). The initial CD4 distribution of HIV-infected adults, 
at the time they acquire HIV, as well as the probabilities of 
transition between the HIV stages in Fig. 1, are set at the rates 
estimated by Hendriks et al.19 from men in Amsterdam from 
1990 to 1996. These rates were selected from several other 
possible sources,19-22 because they produced an estimated 
median HIV survival time consistent with medians estimated 
for South Africa in other studies23,24 and because they produced 
a distribution of CD4+ counts in HIV-infected adults roughly 
consistent with the distributions observed in South African 
surveys.25-27
Assumptions about the annual number of new adult HIV 
infections were obtained from the ASSA2003 AIDS and 
Demographic model.5 The model projects the change in the 
number of infected individuals in the different CD4 stages 
at monthly intervals, adding new infections and removing 
individuals who die or start antiretroviral treatment. Non-
HIV mortality is set at a rate of 0.005 per annum, equal to the 
average non-HIV mortality rate in HIV-positive South African 
adults estimated by the ASSA2003 model. The numbers of 
adults starting antiretroviral treatment in each period are 
set at 90% of the S(t) estimates obtained previously, since 
17
Figure 1: Model of HIV progression in HIV-infected adults
Transitions represented by solid lines are calculated using specified transition probabilities, while
transitions represented by dashed lines are calculated using specified numbers starting antiretroviral
treatment.
CD4
>900
CD4
700 - 900
CD4
500 - 700
CD4
350 - 500
CD4
200 - 350
CD4
<200
AIDS
AIDS
death
Non-HIV
death
Receiving
HAART

Fig. 1. Model of HIV progression in HIV-infected adults. Transitions 
represented by solid lines ar  calcul ted u ing specified tran ition prob-
abilities, while transitions represented by dashed lines are calculated using 
specified numbers starting antiretroviral treatment.
September 2009, Vol. 99, No. 9  SAMJ
ORIGINAL ARTICLES
663
approximately 10% of those receiving antiretroviral treatment 
are children. Based on data from South African treatment 
programmes,17,28,29 we assumed that 35% of adults starting 
treatment had already progressed to AIDS and the balance 
started therapy when their CD4+ count was <200/µl, prior to 
the development of clinical AIDS.
Estimates of unmet need are calculated according to three 
definitions:
1.    conservative criteria that include only adults with untreated 
AIDS
2.    current criteria used by the DOH,4 which include all adults 
with untreated AIDS or a CD4+ count <200/µl
3.    criteria recommended by the Southern African HIV 
Clinicians Society,7 which include all adults with untreated 
AIDS or a CD4+ count <350/µl.
Sensitivity analysis
To assess the sensitivity of the unmet need estimates to key 
variables, the following plausible ranges of parameter values 
are considered. The proportion of adults starting treatment 
who have already progressed to AIDS is varied between 20% 
and 50%,17,28,29 and the rate at which individuals discontinue 
treatment owing to death or loss to follow-up is varied between 
0.7 times and twice the rates estimated from the Western 
Cape data, based on variability in rates of retention observed 
within South Africa.28,30,31 The annual numbers of new HIV 
infections in adults are varied between the upper and lower 
limits of the 95% prediction intervals calculated in a previous 
uncertainty analysis.24 In addition, alternative estimates of rates 
of transition between CD4 stages are considered.19-22
Results
By the middle of 2008, an estimated 568 000 adults and children 
were receiving antiretroviral treatment in South Africa, which is 
more than twice the number 2 years previously, and more than 
10 times the number at the middle of 2004 (Table I). Although 
72% of patients in 2004 were receiving treatment through 
DMPs or WPTPs, this proportion declined to 15% by mid-
2008, following the rapid scaling up of antiretroviral access 
in the public health sector (Fig. 2a). The proportion receiving 
treatment through NGO programmes has remained stable at 
around 6%, though this figure varies substantially between the 
provinces (Fig. 2b).
Over the years 2000 - 2008, the estimated CD4 distribution 
of the HIV-infected adult population changed substantially 
(Fig. 3a). The proportion of infected adults who have a CD4+ 
count >350/µl and are not on treatment has decreased from 
70% in 2000 to 54% in 2008, and the proportion of infected 
adults in need of treatment, by current DoH eligibility criteria, 
has increased from 13% to 25% over this period. However, the 
proportion of infected adults who have CD4+ counts >350/µl 
and are not on treatment was relatively uniform across the 
provinces in 2008, at between 53% and 57% (Fig. 3b).
Antiretroviral coverage in adults has improved substantially, 
rising from 4.9% in 2004 to 40.2% in 2008, according to DoH 
eligibility criteria (Table II). Estimates of coverage change 
substantially when different definitions of treatment eligibility 
are used; when ‘unmet need’ is defined only as untreated 
AIDS, antiretroviral coverage in 2008 is estimated at 54.2%, 
but when ‘unmet need’ is defined according to the Southern 
African HIV Clinicians Society guidelines, coverage is 
Table I. Estimated numbers of adults and children receiving antiretroviral treatment in South Africa, 2001 - 2008
   2001        2002               2003      2004             2005    2006         2007               2008
Cumulatively enrolled
   in public sector  0        0               0        11 000             66 000    180 000         327 000          539 000
Currently enrolled in
   public sector  0        0               0       9 000             59 000    157 000         278 000          449 000
   NGO programmes 0        0               1 000      4 000             6 000    14 000         23 000            32 000
   DMPs, WPTPs  6 000        15 000             25 000      34 000             44 000    57 000         70 000            86 000
Total currently
   enrolled  6 000        15 000             26 000      47 000             109 000    229 000         371 000          568 000
Total, by province
   Eastern Cape (EC) 700        1 700               2 800      5 000             12 100    25 300         41 000            62 000
   Free State (FS)  400        900               1 500      2 200             4 800    9 500         17 000            28 000
   Gauteng (GA)  1 500        3 900               6 400      13 600             30 100    60 000         92 000            139 000
   KwaZulu-Natal (KZ) 2 000        5 100               8 500      12 800             29 800    65 000         107 000          167 000
   Limpopo (LP)  300        700               1 200      1 900             4 600    11 500         20 000            34 000
   Mpumalanga (MP) 500        1 200               2 000      3 100             5 600    11 900         23 000            37 000
   Northern Cape (NC) 100        100               200      400             1 500    3 200         6 000              10 000
   North West (NW)  400        1 000               1 600      2 600             8 500    20 500         33 000            46 000
   Western Cape (WC) 300        800               1 600      5 700             12 000    21 600         31 000            45 000
Figures are rounded to the nearest 1 000, except in the case of the pre-2007 provincial estimates, which are rounded to the nearest 100. All estimates relate to the middle of the specified 
calendar year. 
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estimated at only 22.2% (Fig. 3c). Adult antiretroviral coverage 
also varies greatly between provinces, ranging from 25.8% in 
the Free State to 71.7% in the Western Cape in 2008. Similar 
variability is observed when using the HIV Clinicians Society 
guidelines to define unmet need (Fig. 3d). 
The total number of untreated adults needing antiretroviral 
treatment, at the middle of 2008, is estimated to be around  
760 000 using the DoH eligibility criteria, 430 000 using the 
AIDS sick criterion, and 1.79 million using the HIV Clinicians 
Society criteria (Table III). These estimates of unmet need 
are relatively insensitive to changes in the assumed rates 
of retention on antiretroviral treatment and the assumed 
proportion of those starting treatment who have already 
progressed to AIDS. However, the estimates are very sensitive 
to the uncertainty regarding the 
annual numbers of new HIV 
infections in South Africa; the 
estimated total number of untreated 
adults who are sick with AIDS or 
have a CD4+ count <200/µl changes 
to 480 000 and 1.01 million when 
the lower and upper estimates of 
the annual new adult HIV infections 
are substituted into the model. The 
estimates of unmet need are also 
quite sensitive to the choice of HIV 
progression parameters. Using the 
progression parameters estimated 
by Hendriks et al.19 for men in 
Amsterdam over the 1985 - 1990 
period, the unmet need reduces to 
600 000, but using the progression 
parameters estimated by Longini et 
al.21 for USA military personnel, the 
unmet need increases to 990 000.
Discussion
This study demonstrates significant 
progress in the provision of 
antiretroviral treatment in South 
Africa, particularly after the phasing 
in of antiretroviral treatment 
in the public health sector after 
2003. However, a large unmet 
need for antiretroviral treatment 
remains and, by the middle of 
2008, only 40.2% of adults needing 
antiretroviral treatment were 
receiving it. A significant barrier to 
the expansion of the antiretroviral 
treatment programme is the 
limited number of public health 
facilities providing treatment and 
their shortage of health workers. An urgent need therefore 
exists for greater decentralisation of antiretroviral treatment 
services32 and greater recruitment and retention of health 
workers in the public health sector.33-36 A further barrier to 
improving antiretroviral coverage is the high proportion of 
eligible individuals who are unaware of their HIV status; in 
the 2005 HSRC household survey, for example, only 36% of 
HIV-infected adults had ever been tested for HIV.37 Stigma and 
confusion regarding the efficacy of antiretroviral treatment 
relative to traditional medicines are also significant factors 
inhibiting access to antiretroviral treatment;32 leaders at all 
levels must present clear and consistent messages to overcome 
these barriers.
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Figure 2: Proportions of adults and children treated by different providers
ART = antiretroviral treatment;. DMPs = disease management programmes (including workplace
treatment programmes).; NGO = non-governmental organizsation..
Provincial abbreviations are given in Table 1I. All estimates relate to the middle of the specified
calendar year.
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Fig. 2. Proportions of adults and children treated by different providers. ART = antiretroviral treatment; 
DMPs = disease management programmes (including workplace treatment programmes); NGO = non-
governmental organisation. Provincial abbreviations are given in Table I. All estimates relate to the middle of 
the specified calendar year.
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(b) % of HIV+ adults in different stages in 2008, by province
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(d) % of ART-eligible adults in different stages in 2008, by province
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Figure 3: Proportions of adults in different CD4 and antiretroviral eligibility stages
ART = antiretroviral treatment.
Provincial abbreviations are given in Table 1I. All estimates relate to the middle of the specified
calendar year.
Fig. 3. Proportions of adults in different CD4 and antiretroviral eligibility stages. ART = antiretroviral treat-
ment. Provincial abbreviations are given n Table I. All estimates relate to the middle of the specifi d calendar 
year.
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Our analysis also demonstrates significant inequality 
in access to antiretroviral treatment in South Africa, with 
coverage in mid-2008 ranging from 25.8% in the Free State 
to 71.7% in the Western Cape. This appears to be mostly 
owing to variability in the performance of the public health 
sector, since the provinces with the highest coverage (Western 
Cape and Northern Cape) have the highest proportions of 
patients managed in the public sector, and the provinces with 
low coverage (Free State, Eastern Cape, Mpumalanga and 
Limpopo) have low proportions of patients managed in the 
public sector. The high coverage in the Western Cape and 
Northern Cape could also reflect their relatively low HIV 
prevalence.
We present a novel approach to estimating the unmet 
need for antiretroviral treatment. Although it is possible to 
conduct surveys to measure the unmet need for treatment at 
Table III. Sensitivity analysis of the total unmet need for antiretroviral treatment in adults at the middle of 2008
             Definition of eligibility
               AIDS  DOH            SAHIVCS
               sick   criteria            criteria
Baseline estimate              432 000  760 000            1 795 000
Percentage of adults starting ART with AIDS = 50%          417 000  801 000            1 836 000
Percentage of adults starting ART with AIDS = 20%          457 000  745 000            1 780 000
Rate of death/discontinuation on ART = 0.7 × baseline          437 000  773 000            1 808 000
Rate of death/discontinuation on ART = 2 × baseline          421 000  741 000            1 777 000
New adult HIV infections = lower limit of 95% interval          278 000  476 000            1 227 000
New adult HIV infections = upper limit of 95% interval          568 000  1 011 000            2 226 000
Alternative estimates of HIV progression parameters
   Longini et al., USA army personnel, 1985 - 199022           580 000  992 000            1 769 000
   Satten & Longini, men in San Francisco, 1984 - 199223          403 000  695 000            1 427 000
   Hendriks et al., men in Amsterdam, 1984 - 199321           467 000  802 000            1 667 000
   Hendriks et al., men in Amsterdam, 1985 - 199020           406 000  604 000            1 429 000
   Hendriks et al., men in Vancouver, 1985 - 199020           478 000  622 000            1 341 000
   Hendriks et al., men in Vancouver, 1990 - 199620           565 000  948 000            1 779 000
ART = antiretroviral treatment; DOH = Department of Health; SAHIVCS = Southern African HIV Clinicians Society.
Table II. Estimated antiretroviral coverage in adults (%), according to different definitions of treatment eligibility
           Definition of eligibility
            AIDS   DOH        SAHIVCS
             sick    criteria          criteria
National estimates (by year)
2001             1.9      1.0             0.5
2002             3.9      2.1             1.0
2003             5.6      3.0             1.5
2004             8.8      4.9             2.4
2005           17.1    10.0             5.1
2006           30.1    19.1            10.0
2007           41.6    28.3            15.2
2008           54.2    40.2            22.2
2008 estimates (by province)
Eastern Cape          46.4    32.4            17.5
Free State          38.4    25.8            14.2
Gauteng          57.6    43.5            24.0
KwaZulu-Natal          53.3    39.4            22.1
Limpopo          45.9    32.2            17.4
Mpumalanga          44.6    31.2            17.3
Northern Cape          72.5    61.1            33.3
North West          49.6    35.4            19.6
Western Cape          80.9    71.7            39.9
DOH = Department of Health; SAHIVCS = Southern African HIV Clinicians Society. 
All estimates relate to the middle of the specified calendar year.
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a given time,25, 38 this analysis shows that the CD4 distribution 
in the HIV-infected population can be expected to change 
substantially over time. Since it is costly to conduct surveys, 
mathematical models provide a simple alternative method 
for estimating the change in the unmet need for treatment 
as the epidemic progresses. The Spectrum model employed 
by UNAIDS, for example, estimates unmet need in adults by 
assuming that the CD4+ count in infected adults falls below 
the 350 and 200 thresholds at specified rates, based on CD4 
data from Africa.39 The ASSA2003 model, which is commonly 
used in setting antiretroviral treatment targets in South Africa, 
quantifies unmet need in terms of WHO clinical staging,2 
although this is a poor indication of unmet need according to 
combined CD4 and clinical criteria.38, 40-42 A mathematical model 
proposed by Williams et al.43 estimates unmet need based on 
local CD4 data, but does not incorporate clinical criteria. It 
would therefore appear that few mathematical models exist for 
estimating unmet need according to the combined clinical and 
CD4 criteria that are commonly used in defining antiretroviral 
eligibility.4,6,7
Although our model has the advantage of quantifying unmet 
need in terms of various combinations of clinical and CD4 
criteria, it is, like other models,3,44 parameterised using data 
that are not local to the setting in which the model is applied. 
Since distributions of CD4+ counts in HIV-negative adults and 
rates of CD4 decline in HIV-infected adults differ substantially 
between populations,43, 45 the HIV progression parameters 
that have been calculated from men in Amsterdam could 
be inappropriate for South Africa. We chose the progression 
parameters estimated from men in Amsterdam because they 
yielded the model results most consistent with South African 
data. For example, the model estimates of the proportion 
of untreated adults with CD4+ counts <200 (19%), 200 - 349 
(20%), and 350 - 499 (25%) in 2004, are roughly consistent with 
the ranges measured in  South African surveys between 2002 
and 2005 (10 - 22%, 19 - 28% and 18 - 26% respectively).25-27 
In addition, the median survival time estimated using the 
Amsterdam cohort data (10.8 years in the absence of highly 
active antiretroviral treatment) is roughly consistent with the 
median of 10.5 years estimated for South African gold miners 
aged 25 - 34 at the time of HIV acquisition23 and the median 
of 10.8 years estimated for adults aged 29 at the time of HIV 
acquisition, based on South African mortality data and HIV 
prevalence data.24 This suggests that the HIV progression 
parameters estimated from the Amsterdam cohort serve as a 
reasonable approximation to those in South Africa.
A potential concern is that data on the numbers starting 
treatment in the public sector could be subject to significant 
double-counting,8 and the rates of antiretroviral retention 
estimated from the Western Cape public health sector11 might 
not be applicable to other provinces. However, the estimates 
of numbers currently receiving antiretroviral treatment in the 
public health sector (Table I) are consistent with unpublished 
public sector drug distribution estimates produced by Aspen 
Pharmacare, which suggests that bias owing to double-
counting and inter-provincial differences in antiretroviral 
retention is not substantial. Another limitation is the absence 
of data from some of the smaller DMPs and from individuals 
paying for their own treatment outside of DMPs,15 which may 
result in some under-estimation of antiretroviral coverage. 
Further work is needed to explore definitions of antiretroviral 
coverage other than the standard UNAIDS/UNGASS indicator, 
e.g. the proportion of newly eligible individuals in a given 
year who start treatment. Such measures may provide a more 
accurate indicator of recent programme performance, as they 
are not affected by the numbers of patients enrolled in the past. 
Further work is also required to produce separate estimates 
of antiretroviral coverage in men and women and to develop 
a separate model for estimating antiretroviral coverage in 
children.
We thank the many DMPs and NGOs that provided data from their 
programmes, and Andrew Boulle for providing helpful comments 
on an earlier version of this paper.
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